Can CSL shares hit $200? 3 things that need to go right

CSL shares have climbed above $180 this week and are now eyeing the $200 level, after rising to $180.04—up 6% for the month and 27% over six months. The biotech stock remains about 10% lower over 12 months, however, as investors grapple with pressured earnings and uncertainty about when growth will re-accelerate. Three catalysts are highlighted: Behring must deliver stronger plasma-therapy volumes and profitability while management targets mid-single-digit FY27 revenue growth; Vifor is expected to fall about 25% in FY27 due to generics; and CSL needs further margin expansion after about US$176 million cost savings in FY26.